Search Results - "Imaoka, Takeshi"

Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo- and tamsulosin-controlled 12-week study in Asian men by Yokoyama, Osamu, Yoshida, Masaki, Kim, Sae Chul, Wang, Chii-Jye, Imaoka, Takeshi, Morisaki, Yoji, Viktrup, Lars

“…Objectives To examine the efficacy and safety of tadalafil in Asian men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Methods…”
Get full text

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study by Terauchi, Yasuo, Satoi, Yoichi, Takeuchi, Masakazu, Imaoka, Takeshi

“…The aim of this study was to evaluate the dose-dependent effect of dulaglutide, a glucagon-like peptide-1 receptor agonist, on glycaemic control in Japanese…”
Get full text

Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients with Type 1 Diabetes: PRONTO-T1D Subpopulation Analysis by Miura, Junnosuke, Imori, Makoto, Nishiyama, Hiroshi, Imaoka, Takeshi

“…Introduction We evaluated the efficacy and safety of ultra-rapid lispro (URLi) in comparison to lispro in a subgroup analysis of Japanese adults with type 1…”
Get full text

Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study by Inagaki, Nobuya, MD, PhD, Atsumi, Yoshihito, MD, PhD, Oura, Tomonori, MSc, Saito, Hitoshi, PhD, Imaoka, Takeshi, MD, PhD

“…Abstract Background Exenatide once weekly (QW) is an extended-release formulation of exenatide, a glucagon-like peptide-1 receptor agonist that reportedly…”
Get full text

Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57) by Ishigaki, Yasushi, Strizek, Alena, Aranishi, Toshihiko, Arai, Nobuhiro, Imaoka, Takeshi, Cai, Zhihong, Maegawa, Hiroshi

“…Introduction There are limited real-world data on the prescribing of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes…”
Get full text

Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis by Jinnouchi, Hideaki, Imori, Makoto, Nishiyama, Hiroshi, Imaoka, Takeshi

“…Introduction The aim of this study was to evaluate the efficacy and safety of ultra-rapid lispro (URLi) versus lispro in a subgroup analysis of Japanese adults…”
Get full text

A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial by Emoto, Masanori, Terauchi, Yasuo, Ozeki, Akichika, Oura, Tomonori, Takeuchi, Masakazu, Imaoka, Takeshi

“…The goal of this study was to assess the safety and efficacy of 0.75 mg of dulaglutide, a once weekly glucagon-like peptide-1 receptor agonist, in Japanese…”
Get full text

Efficacy and safety of stepwise introduction of insulin lispro mix 50 in Japanese patients with type 2 diabetes inadequately controlled by oral therapy by Nakashima, Eitaro, Kuribayashi, Nobuichi, Ishida, Kazufumi, Taketsuna, Masanori, Takeuchi, Masakazu, Imaoka, Takeshi

“…The objective of this study was to evaluate the efficacy and safety of stepwise introduction of insulin lispro mix 50 (LM50) from once to 3 times daily in…”
Get full text

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial by Inagaki, Nobuya, Takeuchi, Masakazu, Oura, Tomonori, Imaoka, Takeshi, Seino, Yutaka

“…As the disease progresses, many patients with type 2 diabetes have difficulty in reaching treatment goals. We aimed to assess the efficacy and safety of…”
Get full text

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes : dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study by Yasuo Terauchi, Yoichi Satoi, Masakazu Takeuchi, Takeshi Imaoka

“…[Abstract.] The aim of this study was to evaluate the dose-dependent effect of dulaglutide, a glucagon-like peptide-1 receptor agonist, on glycaemic control in…”
Get full text

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial by Kadowaki, Takashi, Chin, Rina, Ozeki, Akichika, Imaoka, Takeshi, Ogawa, Yoshihiro

“…Due to potential ethnic differences in the pathophysiology of type 2 diabetes, new therapeutics need to be evaluated in Japanese patients. We aimed to assess…”
Get full text

Effects of propofol on left ventricular mechanoenergetics in the excised cross-circulated canine heart by Fujinaka, Waso, Shimizu, Juichiro, Iribe, Gentaro, Imaoka, Takeshi, Oshima, Yu, Kiyooka, Takahiko, Morita, Kiyoshi, Mohri, Satoshi

“…Although propofol is commonly used for general anesthesia, its direct effects on left ventricular (LV) contractility and energetics remain unknown…”
Get full text

A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent : an open-label, nonrandomized, phase 3 trial by Masanori Emoto, Yasuo Terauchi, Akichika Ozeki, Tomonori Oura, Masakazu Takeuchi, Takeshi Imaoka

“…[Abstract.] The goal of this study was to assess the safety and efficacy of 0.75 mg of dulaglutide, a once weekly glucagon-like peptide-1 receptor agonist, in…”
Get full text

A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes by Furihata, Kenichi, Mimura, Hanaka, Urva, Shweta, Oura, Tomonori, Ohwaki, Kenji, Imaoka, Takeshi

“…Aim To investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirzepatide in Japanese participants with type 2 diabetes…”
Get full text

Efficacy and safety of stepwise introduction of insulin lispro mix 50 in Japanese patients with type 2 diabetes inadequately controlled by oral therapy by Eitaro Nakashima, Nobuichi Kuribayashi, Kazufumi Ishida, Masanori Taketsuna, Masakazu Takeuchi, Takeshi Imaoka

“…The objective of this study was to evaluate the efficacy and safety of stepwise introduction of insulin lispro mix 50 (LM50) from once to 3 times daily in…”
Get full text

969-P: Effects of Tirzepatide on Meal Intake and Appetite in Japanese Patients with Type 2 Diabetes by OHWAKI, KENJI, FURIHATA, KENICHI, OURA, TOMONORI, IMAOKA, TAKESHI

“…Dual GIP and GLP-1 receptor agonist, tirzepatide (TZP), showed clinically meaningful HbA1c reduction and dose-dependent weight loss in Japanese patients with…”
Get full text

Celsior Preserved Cardiac Mechanoenergetics Better Than Popular Solutions in Canine Hearts by Oshima, Yu, Mohri, Satoshi, Shimizu, Juichiro, Iribe, Gentaro, Imaoka, Takeshi, Fujinaka, Waso, Kiyooka, Takahiko, Ishino, Kozo, Sano, Shunji, Kajiya, Fumihiko, Suga, Hiroyuki

“…Better protective effects of Celsior on cardiac function than the other conventional solutions have been reported in acute experiments and in clinical trials…”
Get full text

1024-P: Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM by OHWAKI, KENJI, FURIHATA, KENICHI, MIMURA, HANAKA, OURA, TOMONORI, IMAOKA, TAKESHI

“…Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist (RA), has shown superior glycemic control and weight loss compared to a selective GLP-1 RA. A…”
Get full text

Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme) by Kiyosue, Arihiro, Dunn, Julia P., Cui, Xuewei, Hickey, Ana, Hirase, Tetsuaki, Imaoka, Takeshi, Heine, Robert J.

“…Aim To assess the safety and efficacy of tirzepatide in people of East Asian descent based on age and body mass index (BMI). Materials and Methods Data of…”
Get full text

Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study by Shingaki, Tomotaka, Taki, Kentaro, Koyanagi, Momoha, Nagaoka, Soshi, Yoshizawa, Kenichi, Oki, Norika, Yoshikawa, Aki, Imaoka, Takeshi

“…To evaluate the long-term safety and effectiveness of biosimilar insulin glargine (GLY) in real-world clinical practice. This prospective, non-interventional,…”
Get full text